Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XmAb27564 in plaque psoriasis and atopic dermatitis
NCT06005792Phase 1Terminated
- Sponsor
- Xencor
- Start
- Oct 2022
- Primary completion
- Mar 2024
- Modality
- Fc Fusion Proteins, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of XmAb564 in plaque psoriasis and atopic dermatitis (AD) (4 arms), sponsored by Xencor. Primary endpoint: Safety and Tolerability of Multiple Ascending Dose Subcutaneous Administration of XmAb27564 at Day 57. Started Oct 2022; status: terminated.
02
Drugs
XmAb564
03
Conditions
plaque psoriasisatopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06005792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06005792.